Large-scale, prospective clinical trials with multiple biomarkers, such as tau imaging, inflammation markers, or advanced neuropsychological assessments, are warranted to further validate and clarify Ginkgo’s mechanistic role in AD. This evidence concerns the gene MAPT and Alzheimer disease.